VIB-RUG Department of Molecular Biomedical Research

Molecular ImmunoBiotechnology Unit

 

 

 

 

 

 

 

 

 

References to published work

Antibody Engineering

   Articles

Mertens, N., F. Devos, J. Leoen, E. Van Deynse, A. Willems, S. Schoonooghe, I. Burvenich, S. De Koker, D. Vlieghe, J. Grooten, A. Kelly and C. Van de Wiele (2004). "New Strategies in Polypeptide and Antibody Synthesis: an overview." Cancer Biotherapy & Radiopharmaceuticals 19(1): 97-107.

Van de Wiele, C., I. Goethals, K. Audenart, A. Otte and N. Mertens (2004). Molecular Aspects of G-protein Coupled Receptor Signalling of Relevance for Nuclear Medicine Imaging in Psychiatry. Nuclear Medicine in Psychiatry. A. Otte, Springer Verlag: 45-56.

Van de Wiele, C., H. Vermeersch, D. Loose, A. Signore, N. Mertens and R. Dierckx (2004). "Radiolabeled annexin-V for monitoring treatment response in oncology." Cancer Biother Radiopharm 19(2): 189-94.

Willems, A., J. Leoen, S. Schoonooghe, J. Grooten and N. Mertens (2003). "Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives." J Chromatography B 786(1-2): 161-176.

Schoonjans, R., A. Willems, S. Schoonooghe, J. Leoen, J. Grooten and N. Mertens (2001). "A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain." Biomolecular Engineering 17(6): 193-202.

Mertens, N., R. Schoonjans, A. Willems, S. Schoonooghe, J. Leoen and J. Grooten (2001). New Recombinant bi- and trispecific antibody derivatives. Novel Frontiers in the Production of Compounds for Biomedical Use. A. Van Broeckhoven, F. Shapiro and J. Anné. Dordrecht, Kluwer Academic Publishers. 1: 193-205.

Schoonjans, R., A. Willems, J. Grooten and N. Mertens (2000). “Efficient heterodimerization of recombinant bi- and trispecific antibodies.” Bioseparation 9(3): 179-83.

Schoonjans, R., A. Willems, S. Schoonooghe, W. Fiers, J. Grooten and N. Mertens (2000). “Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives.” J Immunol 165(12): 7050-7.

Schoonjans, R., A. Willems, S. Schoonooghe, J. Leoen, J. Grooten and N. Mertens (2001). “A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.” Biomolecular Engineering 17(6): 193-202.

   Patent Applications

Schoonjans, R. and N. Mertens (1998). Novel multipurpose antibody derivatives. WO9937791, EP1049787., VIB.

Mertens, N. and J. Grooten (2002). Novel heterodimeric fusion proteins. WO0202781, VIB  

Expression technology

   Articles

De Wilde, G., N. Mertens, E. Boone, B. De Vreese, J. Van Beeumen, W. Fiers and G. Haegeman (2001). “Expression in Escherichia coli of the Death Domain of the Human p55 Tumor Necrosis Factor Receptor.” Protein Expr Purif 23(2): 226-32.

Mertens, N., W. Fiers and E. Remaut (1999). An advanced vector system for high-level recombinant gene expression in E. coli. Biotechnology International II: Latest developments in the Biotechnology industrie and research. T. H. Connor, H. U. Weier and F. Fox. San Francisco, Universal Medical Press. 2: 165-172.

Mertens, N., E. Remaut and W. Fiers (1996). “Increased stability of phage T7g10 mRNA is mediated by either a 5'- or a 3'-terminal stem-loop structure.” Biol Chem 377(12): 811-7.

Mertens, N., E. Remaut and W. Fiers (1995). “Tight transcriptional control mechanism ensures stable high-level expression from T7 promoter-based expression plasmids.” Biotechnology (N Y) 13(2): 175-9.

Mertens, N., E. Remaut and W. Fiers (1995). “Versatile, multi-featured plasmids for high-level expression of heterologous genes in Escherichia coli: overproduction of human and murine cytokines.” Gene 164(1): 9-15.

Guisez, Y., J. Demolder, N. Mertens, A. Raeymaekers, G. Plaetinck, J. Robbens, J. Vandekerckhove, E. Remaut and W. Fiers (1993). “High-level expression, purification, and renaturation of recombinant murine interleukin-2 from Escherichia coli.” Protein Expr Purif 4(3): 240-6.

Fiers, W., R. Contreras, J. Demolder, N. Mertens, E. Remaut and J. Robbens (1992). Expression of cytokine genes in E.coli and in yeast. Bio-Engineering. 8: 18.

Patent Applications

Mertens, N., E. Remaut and W. Fiers (1997). Regulatory system for inducible expression of genes with lambdoid promoters. WO9848025, VIB.

 

Awards

bullet

Laureate of "Vlaamse Liga tegen Kanker" 1999 to R. Schoonjans

Development of bispecific and multifunctional antibody derivatives

bullet

First poster prize at the 2001 IBC Antibody Engineering meeting (San Diego) to N. Mertens

New recombinant trispecific antibodies 

An WILLEMS, Jannick LEOEN, Reinhilde SCHOONJANS, Steve SCHOONOOGHE, Johan GROOTEN and Nico MERTENS

bullet

Second prize at the 2002 Amersham Biotech European Contest for Young Scientist at the workshop "From Gene to Functional Protein" (Paris) to A. Willems

Production and purification of multivalent antibody fragments

An Willems,  Jannick Leoen, Steve Schoonooghe,  Johan Grooten and Nico Mertens

bullet

First poster price at the 2004 Protein Expression and Purification meeting (PEPtalk San Diego, US) to N. Mertens

A parallel cloning expression-system for fast screening of optimal expression strategies in E. coli

Nico Mertens, Els Van Deynse, Jannick Leoen, Patrick Santambien, Pedro de Norhonha Pissarra  and Andrew Kelly

 

 
Home

Contact

Research projects

Publications

After eight

Check out 

links to:

MABs on the market
Antibody Companies
Immune Therapy Companies
Custom protein expression and purification
Biotech in Flanders
Flanders Universities
Flanders Biotech Policy

                  

© 2002 Webmaster